Literature DB >> 25788166

Significance of p53 expression in background endometrium in endometrial carcinoma.

Thuy Thi Nguyen1, Toru Hachisuga, Rie Urabe, Tomoko Kurita, Seiji Kagami, Toshinori Kawagoe, Shohei Shimajiri, Kazuki Nabeshima.   

Abstract

The p53 signature (p53S) has been proposed to be a marker of the earliest phase of development of endometrial serous carcinoma. We examined the presence of p53S in the background endometrium in cases of endometrial carcinoma. From a series of 351 endometrial carcinomas, 225 (64.1 %) lesions, for which slides of the adjacent noncancerous endometrium were available for review, were included. Expression of estrogen receptor (ER)-alpha, Ki-67, and p53 in the adjacent endometrium was studied by immunohistochemistry. The p53S was defined as the presence of morphologically benign endometrial epithelial cells with moderate to strong intensity of p53 immunostaining. Of the 225 noncancerous endometrium samples, 34 consisted of hyperplastic and 191 of non-hyperplastic endometrium. A p53S was found in 22 cases (mean age 64.2 years), 2 in hyperplastic, and 20 in non-hyperplastic background endometrium. All p53S-positive cases also expressed ER-alpha; their median Ki-67 labeling index (LI) was 4.0 % (range 0.0 to 21.0 %). The two cases with hyperplastic p53S-positive background endometrium were in association with a grade 1 endometrioid tumor in a premenopausal woman with Lynch syndrome. Of the 152 cases of endometrioid adenocarcinomas with non-hyperplastic endometrium, 12 (8 %) were p53S positive, none of which associated with EIC. Of the 21 cases of serous carcinoma, five (24 %) were p53S positive, 4 of which (19 %) associated with EIC while in 5 others (24 %) EIC was found without p53S. Of three clear cell adenocarcinomas, none were p53S positive while two contained EIC without p53S. Of 15 carcinosarcomas, 3 (20 %) were p53S positive, all of which with EIC while 6 others (40 %) were associated with EIC but without p53S. Of the 8 non-endometrioid tumors with p53S, 7 (88 %) were associated with EIC. p53S is thought to be associated with precancerous lesions of non-endometrioid tumors, including carcinosarcomas.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25788166     DOI: 10.1007/s00428-015-1752-5

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  21 in total

1.  BRCA, the oviduct, and the space and time continuum of pelvic serous carcinogenesis.

Authors:  Christopher P Crum; Frank D McKeon; Wa Xian
Journal:  Int J Gynecol Cancer       Date:  2012-05       Impact factor: 3.437

2.  IMP2 expression distinguishes endometrioid from serous endometrial adenocarcinomas.

Authors:  Liping Zhang; Yuxin Liu; Suyang Hao; Bruce A Woda; Di Lu
Journal:  Am J Surg Pathol       Date:  2011-06       Impact factor: 6.394

3.  Estrogen receptor expression and increased risk of lymphovascular space invasion in high-grade serous ovarian carcinoma.

Authors:  Koji Matsuo; Todd B Sheridan; Seiji Mabuchi; Kiyoshi Yoshino; Kosei Hasegawa; Kimberley D Studeman; Dwight D Im; Neil B Rosenshein; Lynda D Roman; Anil K Sood
Journal:  Gynecol Oncol       Date:  2014-03-25       Impact factor: 5.482

Review 4.  A proposed model for endometrial serous carcinogenesis.

Authors:  Wenxin Zheng; Li Xiang; Oluwole Fadare; Beihua Kong
Journal:  Am J Surg Pathol       Date:  2011-01       Impact factor: 6.394

5.  Ki-67, Bcl-2 and p53 expression in endometrial polyps and in the normal endometrium during the menstrual cycle.

Authors:  Hugo Maia; Amélia Maltez; Eduardo Studart; Célia Athayde; Elsimar M Coutinho
Journal:  BJOG       Date:  2004-11       Impact factor: 6.531

Review 6.  The role of the human DNA mismatch repair gene hMSH2 in DNA repair, cell cycle control and apoptosis: implications for pathogenesis, progression and therapy of cancer.

Authors:  Markus Seifert; Jörg Reichrath
Journal:  J Mol Histol       Date:  2006-11-02       Impact factor: 2.611

7.  A candidate precursor to pelvic serous cancer (p53 signature) and its prevalence in ovaries and fallopian tubes from women with BRCA mutations.

Authors:  Ann K Folkins; Elke A Jarboe; Aasia Saleemuddin; Yonghee Lee; Michael J Callahan; Ronny Drapkin; Judy E Garber; Michael G Muto; Shelley Tworoger; Christopher P Crum
Journal:  Gynecol Oncol       Date:  2008-03-14       Impact factor: 5.482

8.  Utility of p16 expression for distinction of uterine serous carcinomas from endometrial endometrioid and endocervical adenocarcinomas: immunohistochemical analysis of 201 cases.

Authors:  Anna Yemelyanova; Hongxiu Ji; Ie-Ming Shih; Tian-Li Wang; Lee-Shu-Fune Wu; Brigitte M Ronnett
Journal:  Am J Surg Pathol       Date:  2009-10       Impact factor: 6.394

9.  Scoring of p16(INK4a) immunohistochemistry based on independent nuclear staining alone can sufficiently distinguish between endocervical and endometrial adenocarcinomas in a tissue microarray study.

Authors:  Chih-Ping Han; Lai-Fong Kok; Po-Hui Wang; Tina S Wu; Yeu-Sheng Tyan; Ya-Wen Cheng; Ming-Yung Lee; Shun-Fa Yang
Journal:  Mod Pathol       Date:  2009-04-03       Impact factor: 7.842

10.  Evidence for a latent precursor (p53 signature) that may precede serous endometrial intraepithelial carcinoma.

Authors:  Elke A Jarboe; Ellen S Pizer; Alexander Miron; Nick Monte; George L Mutter; Christopher P Crum
Journal:  Mod Pathol       Date:  2009-01-16       Impact factor: 7.842

View more
  4 in total

1.  Expression of immune checkpoint molecules in endometrial carcinoma.

Authors:  Jia Liu; Yuling Liu; Wuliang Wang; Chenyang Wang; Yanhong Che
Journal:  Exp Ther Med       Date:  2015-08-28       Impact factor: 2.447

2.  Loss of the p53 transactivation domain results in high amyloid aggregation of the Δ40p53 isoform in endometrial carcinoma cells.

Authors:  Nataly Melo Dos Santos; Guilherme A P de Oliveira; Murilo Ramos Rocha; Murilo M Pedrote; Giulia Diniz da Silva Ferretti; Luciana Pereira Rangel; José A Morgado-Diaz; Jerson L Silva; Etel Rodrigues Pereira Gimba
Journal:  J Biol Chem       Date:  2019-04-26       Impact factor: 5.157

3.  Effect of menopause on hormonal receptors in ampullae of the fallopian tube with a special reference to the p53 signature.

Authors:  Rie Urabe; Toru Hachisuga; Taeko Ueda; Toshinori Kawagoe; Tomoko Kurita; Seiji Kagami; Masanori Hisaoka; Yoshihisa Fujino
Journal:  Int J Womens Health       Date:  2017-03-30

Review 4.  New Insights into Endometrial Cancer.

Authors:  Laura Paleari; Silvia Pesce; Mariangela Rutigliani; Marco Greppi; Valentina Obino; Franco Gorlero; Valerio Gaetano Vellone; Emanuela Marcenaro
Journal:  Cancers (Basel)       Date:  2021-03-24       Impact factor: 6.639

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.